Angioedema Treatment Market to Surge Past USD 30.3 billion by 2035 | FMI

The global angioedema treatment market is poised for remarkable expansion, rising from an estimated USD 6.5 billion in 2025 to USD 30.3 billion by 2035. This surge, driven by a robust CAGR of 16.6%, reflects growing awareness of hereditary and acquired angioedema, alongside advances in targeted therapies. As both patients and healthcare providers place a stronger emphasis on early diagnosis and effective management, therapeutic options ranging from antihistamines to cutting-edge biologics are gaining traction across hospitals, clinics, and research institutions.

The condition, which involves sudden swelling beneath the skin or mucous membranes, is not only painful but also life-threatening in severe cases. Its rising prevalence—particularly among populations with increasing allergy rates and exposure to drug-induced triggers—has elevated the importance of rapid and effective treatment. The expansion of specialized treatment centers, regulatory support for orphan drugs, and strong investments in clinical research are together reshaping the market landscape.

Full Market Report available for delivery. For purchase or customization, please request here: https://www.futuremarketinsights.com/reports/sample/rep-gb-1712

Key Growth Drivers

Rising Prevalence and Emergency Care Needs

The increasing frequency of hereditary and acquired angioedema is a central growth catalyst. More patients are seeking emergency care during acute attacks, underscoring the demand for rapid-response therapies. Hospitals, with their advanced facilities and immediate access to critical drugs, remain the frontline treatment centers, capturing over half the end-use market share in 2025.

Technological Advancements in Treatment

Drug development is advancing at an unprecedented pace. Beyond antihistamines and corticosteroids, novel biologics and genome editing technologies such as CRISPR are offering promising results for hereditary angioedema patients. These innovations reduce attack frequency and improve long-term quality of life, signaling a major shift toward precision medicine.

Supportive Regulatory and Research Frameworks

Governments and health organizations are investing heavily in R&D, providing incentives for orphan drug designations and fostering collaborations between pharmaceutical firms and academic institutions. Such initiatives are creating fertile ground for both established companies and emerging players to bring novel solutions to market.

Segmental Analysis

Drug Class: Antihistamines Take the Lead

Antihistamines are projected to dominate the drug class segment with a 33.2% market share in 2025. Their effectiveness in managing histamine-mediated cases, rapid onset of action, and widespread availability in both oral and injectable forms make them the cornerstone of treatment. Cost-effectiveness further reinforces their adoption, especially in emerging economies. The continuous development of second- and third-generation formulations with fewer side effects ensures their sustained leadership.

End Use: Hospitals as the Preferred Setting

Hospitals will account for 52.3% of the market in 2025, reflecting their central role in handling acute episodes that require immediate intervention. Equipped with intensive care units, specialist teams, and access to intravenous therapies, hospitals remain the safest environment for angioedema patients. Beyond emergency care, hospitals also drive innovation by serving as hubs for clinical trials and training programs.

Regional and Country-Level Outlook

The market’s growth trajectory varies widely across regions, highlighting diverse healthcare infrastructure and awareness levels.

• North America leads in terms of revenue share, supported by a high prevalence of allergies and strong healthcare systems. The U.S. market alone is projected to grow from USD 2.5 billion in 2025 to USD 9.2 billion by 2035, at a CAGR of 14.1%.
• Europe continues to expand steadily, with Germany at the forefront, recording a 19.1% CAGR. France and the UK are also contributing significantly due to advanced hospital care and government support.
• Asia-Pacific is the fastest-growing region, led by China at 22.4% CAGR and India at 20.8%. Rising healthcare investment, a large patient base, and rapid urbanization are fueling adoption.
• Latin America and the Middle East & Africa show moderate but positive growth, with Brazil registering a CAGR of 12.5%. Although growth here is slower, increasing awareness campaigns and hospital expansions are building momentum.

Market Dynamics

The angioedema treatment market is at a crossroads where traditional drugs meet cutting-edge therapies. Corticosteroids and vasopressors continue to play essential roles, but biologics and gene therapies are rewriting the future. CRISPR-based innovations have already shown success in reducing swelling episodes for hereditary angioedema patients. Meanwhile, the rising cases of drug-induced angioedema, often linked to blood pressure medications, are creating demand for alternative treatments and careful patient monitoring.

Despite these advancements, challenges remain. The condition cannot be completely cured, and the reliance on long-term medication raises issues of cost, compliance, and side effects. In regions with limited healthcare infrastructure, awareness gaps and affordability remain major barriers to access.

Request Market Research Draft Report: https://www.futuremarketinsights.com/reports/angioedema-treatment-market

Competitive Landscape

The market is characterized by a blend of established pharmaceutical leaders and emerging biotech firms, all working toward one common goal: effective, accessible, and sustainable treatment for angioedema.

• Shire plc., now part of Takeda, continues to lead with a strong portfolio of therapies for hereditary angioedema.
• CSL Limited is leveraging its expertise in immunoglobulins to expand treatment options for patients.
• Pharming Group NV is making significant strides with its biologics pipeline, particularly targeting hereditary forms of the condition.
• Ionis Pharmaceuticals, Inc. is focusing on RNA-targeted therapies, bringing fresh approaches to treatment development.
• iBio Inc. and BioCryst Pharmaceuticals, Inc. represent the wave of innovative biotech firms bringing niche, high-potential treatments into the spotlight.

These companies are not only investing in clinical trials but also in expanding distribution networks, ensuring patients worldwide can access life-saving drugs. Collaborations with research institutions, co-development agreements, and licensing deals are becoming common strategies to accelerate innovation.

Future Outlook

Looking ahead, the angioedema treatment market is expected to transform from reliance on symptomatic relief to personalized, targeted therapies. As biologics and gene-editing technologies mature, treatment will shift toward prevention and long-term management rather than episodic care.

Hospitals will remain the central hub for acute management, but clinics and research organizations are likely to gain prominence as outpatient and preventative care models expand. Meanwhile, the integration of digital health tools—such as mobile apps for attack monitoring and AI-based predictive analytics—will enhance patient outcomes and reduce healthcare burdens.

The rising burden of allergies worldwide, affecting nearly half of children and a third of adults in some regions, underscores the urgency of continued innovation. By 2035, the angioedema treatment market is expected not only to be larger in size but also to embody a new standard of care that balances effectiveness, accessibility, and sustainability.

Related Reports:

Next Generation Optical Biometry Devices Market: https://www.futuremarketinsights.com/reports/next-generation-optical-biometry-devices-market

Photorejuvenation Equipment Market: https://www.futuremarketinsights.com/reports/photorejuvenation-equipment-market

Pharma Grade Synthetic Camphor Market: https://www.futuremarketinsights.com/reports/pharma-grade-synthetic-camphor-market

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:     

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com

Website: https://www.futuremarketinsights.com

LinkedIn| Twitter| Blogs | YouTube